Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDRALAZINE HYDROCHLORIDE W HYDROCHLOROTHIAZIDE 25 25.
BENZTHIAZIDE vs HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral resistance through relaxation of vascular smooth muscle, likely via nitric oxide-mediated increases in cGMP. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption and decreasing plasma volume.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
One tablet orally twice daily, titrated based on blood pressure response; maximum dose: one tablet four times daily.
None Documented
None Documented
Clinical Note
moderateBenzthiazide + Mecamylamine
"The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Benzthiazide
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide."
Terminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Hydralazine: 2-8 hours (terminal half-life; prolonged in renal impairment; acetylator phenotype affects clearance); Hydrochlorothiazide: 6-15 hours (terminal half-life; increased in renal impairment).
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Hydralazine: 80% renal (as metabolites, 5-10% unchanged); Hydrochlorothiazide: 95% renal (as unchanged drug).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic